ArticleScientific reports2025
Design, synthesis, characterization, biological investigation and docking studies of newly synthesized sulphonyl hydrazide and their derivatives.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antioxidant and Antidiabetic Activity of the Bulb Extract ofAntioxidants (Basel, Switzerland) · 2026Article
- Design, Synthesis, and Biological Evaluation of Novel N-Acyl Sulfonohydrazides Derived From β-Hydroxy Esters: Anticancer, Antioxidant, and Antimicrobial Activities.Chemical biology & drug design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous medications, including non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are available to treat inflammation. However, due to their side effects, the search for new anti-inflammatory drugs remains a major research focus. The current study addresses the synthesis, characterization of sulphonyl hydrazide, followed by in vitro and in silico analyses. Sulphonyl hydrazide compounds (R1-R5) were synthesized and characterized using physicochemical and spectroscopic methods, followed by anti-inflammatory evaluation and in silico approaches. The COX-2 and 5-LOX pathways were used for anti-inflammatory potential of compounds. The test compounds (R1-R5) showed significant activity (P < 0.05) against various in vitro enzymes. The compound R3 exhibited remarkable potency in inhibiting both COX-2 and 5-LOX, at various concentrations with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.